[Latest] Global Active Wound Care Market Size/Share Worth USD14190 Million by 2030 at a 5.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value, Analysis, Outlook)
06. November 2022 21:30 ET
|
Custom Market Insights
Sandy, Utah, USA, Nov. 06, 2022 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Active Wound Care Market Size, Trends and Insights By Type (Exudate Management,...
Misonix Announces Results of New Large Real-World Studies That Further Prove the Clinical Effectiveness of TheraSkin
05. Dezember 2019 09:30 ET
|
MISONIX, Inc.
FARMINGDALE, N.Y., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and...
Misonix, Inc. Enters Into Definitive Agreement to Acquire Regenerative Medical Company Solsys Medical for Approximately $97 Million
02. Mai 2019 16:01 ET
|
MISONIX, Inc.
Transaction Creates Medical Device Company with Comprehensive Portfolio of Wound Care Solutions to Improve Healthcare Outcomes Combined Entity to Generate Over $80 Million in Annual Revenue for...
Kerecis Fish-Skin Technology Named One of the Top Ten Innovations in Podiatry
25. Juli 2017 09:00 ET
|
Kerecis
ARLINGTON, Va., July 25, 2017 (GLOBE NEWSWIRE) -- Podiatry Today has named the Kerecis™ Omega3 Wound fish-skin graft as one of the top 10 innovations in podiatry. The product is the only...
FDA Clears Fish-Skin Technology to Heal Human Wounds
07. November 2013 10:55 ET
|
Kerecis
REYKJAVIK, ICELAND and ISAFJORDUR, ICELAND--(Marketwired - Nov 7, 2013) - Kerecis Limited announced today that a 510(k) clearance has been received from the Food and Drug Administration (FDA)...
Kerecis Completes Successful Immunology Study
03. Mai 2013 03:05 ET
|
Kerecis
DENVER, CO--(Marketwired - May 3, 2013) - Symposium on Advanced Wound Care -- Kerecis today announced that its recent clinical trial found no allergenic reactions to its fish-skin-composed MariGen...
Clinical Trial Demonstrates Safety and Efficacy of Wound-Healing Treatment
06. Oktober 2011 16:29 ET
|
Kerecis
REYKJAVIK, ICELAND and ISAFJORDUR, ICELAND--(Marketwire - Oct 6, 2011) - Kerecis, the emerging tissue-regeneration company, has successfully completed the first human clinical trial of its MariGen...
Kerecis Limited Receives ISO 13485:2003 Quality Management System Certification
25. März 2011 11:00 ET
|
Kerecis
REYKJAVIK, ICELAND and ISAFJORDUR, ICELAND--(Marketwire - March 25, 2011) - Kerecis Limited, the emerging tissue-regeneration company, has received the International Organization for Standardization...